MedTrace Logo

A Study to Assess Ulimorelin in Healthy Subjects

NCT02993055 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2018-05-30

No results posted yet for this study

Summary

A Phase I dose escalation study involving healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

Ulimorelin

OTHER

Placebo

Sponsors & Collaborators

  • Lyric Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-11-30
Completion
2015-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993055 on ClinicalTrials.gov